{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:43:31Z","timestamp":1790786611526,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2009633"],"award-info":[{"award-number":["APP2009633"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016005","name":"Yulgilbar Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jamda.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Medical Directors Association"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.jamda.2023.03.003","type":"journal-article","created":{"date-parts":[[2023,4,8]],"date-time":"2023-04-08T00:06:44Z","timestamp":1680912404000},"page":"773-781.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Systematic Review of Psychotropic Adverse Drug Event Monitoring Tools for Use in Long-Term Care Facilities"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-4794","authenticated-orcid":false,"given":"Brigid E.","family":"McInerney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda J.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin P.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Simon","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jamda.2023.03.003_bib1","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/bmjqs-2021-014280","article-title":"Epidemiology of adverse drug events and medication errors in four nursing homes in Japan: the Japan Adverse Drug Events (JADE) Study","volume":"31","author":"Ayani","year":"2022","journal-title":"BMJ Qual Saf"},{"key":"10.1016\/j.jamda.2023.03.003_bib2","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0002-9343(00)00451-4","article-title":"Incidence and preventability of adverse drug events in nursing homes","volume":"109","author":"Gurwitz","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.jamda.2023.03.003_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.amjmed.2004.09.018","article-title":"The incidence of adverse drug events in two large academic long-term care facilities","volume":"118","author":"Gurwitz","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.jamda.2023.03.003_bib4","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s00228-016-2084-3","article-title":"Drug-related hospital admissions among old people with dementia","volume":"72","author":"Gustafsson","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jamda.2023.03.003_bib5","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/0004867418758919","article-title":"More action needed: psychotropic prescribing in Australian residential aged care","volume":"53","author":"Westbury","year":"2019","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.jamda.2023.03.003_bib6","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1111\/j.1532-5415.2011.03500.x","article-title":"Beyond the prescription: medication monitoring and adverse drug events in older adults","volume":"59","author":"Steinman","year":"2011","journal-title":"JAGS"},{"key":"10.1016\/j.jamda.2023.03.003_bib7","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00228-007-0283-7","article-title":"Adverse drug effects in elderly people - A disparity between clinical examination and adverse effects self-reported by the patient","volume":"63","author":"Lampela","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jamda.2023.03.003_bib8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjopharm.2006.09.011","article-title":"Epidemiology of medication-related adverse events in nursing homes","volume":"4","author":"Handler","year":"2006","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.jamda.2023.03.003_bib9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1176\/appi.ajp.2015.173501","article-title":"The American Psychiatric Association Practice Guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia","volume":"173","author":"Reus","year":"2016","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jamda.2023.03.003_bib11","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/ene.14412","article-title":"A\u00a0European Academy of Neurology guideline on medical management issues in dementia","volume":"27","author":"Frederiksen","year":"2020","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jamda.2023.03.003_bib13","series-title":"Clinical Guidelines Dementia: Assessment, management and support for people living with dementia and their carers","year":"2018"},{"key":"10.1016\/j.jamda.2023.03.003_bib14","series-title":"Clinical Practice Guidelines for the Appropriate Use of Psychotropic Medications in People Living With Dementia and in Residential Aged Care","year":"2022"},{"key":"10.1016\/j.jamda.2023.03.003_bib15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12888-021-03162-w","article-title":"Applicability of somatic monitoring instructions in clinical practice guidelines on antipsychotic drug use","volume":"21","author":"Brouwer","year":"2021","journal-title":"BMC Psychiatr"},{"key":"10.1016\/j.jamda.2023.03.003_bib16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40266-020-00825-3","article-title":"Nurses\u2019, pharmacists\u2019 and family physicians\u2019 perceptions of psychotropic medication monitoring in Australian long-term care facilities: a qualitative framework analysis","volume":"38","author":"Langford","year":"2020","journal-title":"Drugs Aging"},{"key":"10.1016\/j.jamda.2023.03.003_bib17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1466-7657.2004.00251.x","article-title":"Monitoring adverse drug reactions: scales, profiles, and checklists","volume":"51","author":"Jordan","year":"2004","journal-title":"Int Nurs Rev"},{"key":"10.1016\/j.jamda.2023.03.003_bib18","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.psychres.2014.05.060","article-title":"A\u00a0review of self-report medication side effect questionnaires for mental health patients","volume":"219","author":"Ashoorian","year":"2014","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.jamda.2023.03.003_bib19","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1177\/0004867415608244","article-title":"Antipsychotic medication side effect assessment tools: A systematic review","volume":"50","author":"Stomski","year":"2016","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.jamda.2023.03.003_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A\u00a0Rating scale for extrapyramidal side effects","volume":"45","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jamda.2023.03.003_bib21","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A\u00a0Rating scale for drug-induced Akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jamda.2023.03.003_bib22","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0006-3223(94)91257-2","article-title":"A\u00a0rating scale for acute drug-induced Akathisia: development, reliability, and validity","volume":"35","author":"Sachdev","year":"1994","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jamda.2023.03.003_bib23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-1781(97)03031-X","article-title":"The Maryland Psychiatric Research Center scale and the characterization of involuntary movements","volume":"70","author":"Cassady","year":"1997","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.jamda.2023.03.003_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/00001786-200004000-00007","article-title":"Establishment of interrater reliability for a nursing Extrapyramidal Side Effects (EPS) assessment scale","volume":"14","author":"Fagan-Pryor","year":"2000","journal-title":"J\u00a0Nurs Care Qual"},{"key":"10.1016\/j.jamda.2023.03.003_bib25","first-page":"233","article-title":"Extrapyramidal Symptom Rating Scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.jamda.2023.03.003_bib26","first-page":"222","article-title":"The hillside Akathisia scale: a new rating instrument for neuroleptic-induced Akathisia","volume":"25","author":"Fleischhacker","year":"1989","journal-title":"Psychopharmacol Bull"},{"key":"10.1016\/j.jamda.2023.03.003_bib27","first-page":"94","article-title":"Assessment of extrapyramidal symptoms during acute neuroleptic treatment","volume":"56","author":"Mazure","year":"1995","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jamda.2023.03.003_bib28","series-title":"ECDEU Assessment Manual for Psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1016\/j.jamda.2023.03.003_bib29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1017\/S1092852900022045","article-title":"An Innovative approach to clinical communication in schizophrenia: the approaches to schizophrenia communication checklists","volume":"6","author":"Dott","year":"2001","journal-title":"CNS Spectr"},{"key":"10.1016\/j.jamda.2023.03.003_bib30","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1192\/bjp.166.5.650","article-title":"A\u00a0self-rating scale for measuring neuroleptic side-effects. Validation in a group of schizophrenic patients","volume":"166","author":"Day","year":"1995","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jamda.2023.03.003_bib31","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/0269881107087976","article-title":"A\u00a0new self-rating scale for detecting atypical or second-generation antipsychotic side effects","volume":"22","author":"Waddell","year":"2008","journal-title":"J\u00a0Psychopharmacol"},{"key":"10.1016\/j.jamda.2023.03.003_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2045125313510195","article-title":"SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects","volume":"4","author":"Haddad","year":"2014","journal-title":"Ther Adv Psychopharmacol"},{"key":"10.1016\/j.jamda.2023.03.003_bib35","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jamda.2023.03.003_bib36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1023\/A:1015291021312","article-title":"Assessing health status and quality-of-life instruments: attributes and review criteria","volume":"11","author":"Lohr","year":"2002","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jamda.2023.03.003_bib37","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jclinepi.2006.03.012","article-title":"Quality criteria were proposed for measurement properties of health status questionnaires","volume":"60","author":"Terwee","year":"2007","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jamda.2023.03.003_bib38","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jamda.2008.07.002","article-title":"Quality improvement in long term care: the Psychotropic Assessment Tool (PAT)","volume":"9","author":"Dahl","year":"2008","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1016\/j.jamda.2023.03.003_bib39","doi-asserted-by":"crossref","first-page":"e0220885","DOI":"10.1371\/journal.pone.0220885","article-title":"Nurse-led medicines' monitoring in care homes, implementing the Adverse Drug Reaction (ADRe) Profile improvement initiative for mental health medicines: An observational and interview study","volume":"14","author":"Jordan","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jamda.2023.03.003_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/843621","article-title":"Medication Monitoring for People with Dementia in Care Homes: The Feasibility and Clinical Impact of Nurse-Led Monitoring","volume":"2014","author":"Jordan","year":"2014","journal-title":"Sci World J"},{"key":"10.1016\/j.jamda.2023.03.003_bib41","doi-asserted-by":"crossref","first-page":"e0140203","DOI":"10.1371\/journal.pone.0140203","article-title":"Nurse-led medicines' monitoring for patients with dementia in care homes: a pragmatic cohort stepped wedge cluster randomised trial","volume":"10","author":"Jordan","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jamda.2023.03.003_bib42","first-page":"120","article-title":"Assessment of an adverse drug reaction monitoring program in nursing homes","volume":"38","author":"Soon","year":"1985","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.jamda.2023.03.003_bib43","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4236\/ojpsych.2014.42020","article-title":"Improving the appropriateness of antipsychotic prescribing for behavioral and psychological symptoms of dementia (BPSD): a pilot study of the psychotropic use monitoring (PUM) program","volume":"4","author":"Yap","year":"2014","journal-title":"Open J Psychiatr"},{"key":"10.1016\/j.jamda.2023.03.003_bib44","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.2147\/CIA.S178216","article-title":"Development of a tool for monitoring the prescribing of antipsychotic medications to people with dementia in general practice: a modified eDelphi consensus study","volume":"13","author":"Jennings","year":"2018","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.jamda.2023.03.003_bib45","doi-asserted-by":"crossref","first-page":"e023377","DOI":"10.1136\/bmjopen-2018-023377","article-title":"Nurse-led medicines' monitoring in care homes study protocol: a process evaluation of the impact and sustainability of the adverse drug reaction (ADRe) profile for mental health medicines","volume":"8","author":"Jordan","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jamda.2023.03.003_bib46","doi-asserted-by":"crossref","first-page":"596","DOI":"10.2337\/diacare.27.2.596","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","author":"Clark","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jamda.2023.03.003_bib47","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1176\/appi.ajp.2008.08081218","article-title":"Metabolic changes associated with second-generation antipsychotic use in Alzheimer's disease patients: the CATIE-AD study","volume":"166","author":"Zheng","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jamda.2023.03.003_bib48","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.jamda.2021.04.013","article-title":"Potential overtreatment and undertreatment of type 2 diabetes mellitus in long-term care facilities: a systematic review","volume":"22","author":"Stasinopoulos","year":"2021","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1016\/j.jamda.2023.03.003_bib50","series-title":"Health Measurement Scales: A Practical Guide to Their Development and Use","author":"Streiner","year":"2015"},{"key":"10.1016\/j.jamda.2023.03.003_bib51","article-title":"Development of the nurses' observation scale for cognitive abilities (NOSCA)","volume":"2011","author":"Persoon","year":"2011","journal-title":"ISRN Nurs"},{"key":"10.1016\/j.jamda.2023.03.003_bib52","doi-asserted-by":"crossref","first-page":"11877","DOI":"10.3390\/ijerph182211877","article-title":"Patient-reported questionnaires to identify adverse drug reactions: a systematic review","volume":"18","author":"Lim","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jamda.2023.03.003_bib53","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jamda.2016.12.069","article-title":"Comprehensive literature review of factors Influencing Medication Safety in Nursing Homes: Using a Systems Model","volume":"18","author":"Al-Jumaili","year":"2016","journal-title":"J\u00a0Am Med Dir Assoc"},{"key":"10.1016\/j.jamda.2023.03.003_bib54","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1111\/bcp.14824","article-title":"Pharmacist-led interventions to reduce adverse drug events in older people living in residential aged care facilities: A systematic review","volume":"87","author":"Ali","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jamda.2023.03.003_bib55","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1532-5415.2011.03418.x","article-title":"Effect of a pharmacist-led multicomponent intervention focusing on the medication monitoring phase to prevent potential adverse drug events in nursing homes","volume":"59","author":"Lapane","year":"2011","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.jamda.2023.03.003_bib56","doi-asserted-by":"crossref","first-page":"104391","DOI":"10.1016\/j.archger.2021.104391","article-title":"Efficacy, feasibility and acceptability of the OptiMEDs tool for multidisciplinary medication review in nursing homes","volume":"95","author":"Wauters","year":"2021","journal-title":"Arch Gerontol Geriatr"},{"key":"10.1016\/j.jamda.2023.03.003_bib57","first-page":"798","article-title":"Potential side effects and adverse events of antipsychotic use for residents with dementia in assisted living: implications for prescribers, staff, and families","volume":"41","author":"Beeber","year":"2022","journal-title":"J\u00a0Appl Gerontol"},{"key":"10.1016\/j.jamda.2023.03.003_bib58","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/1403494815591719","article-title":"Feasibility of a practical nurse administered risk assessment tool for drug-related problems in home care","volume":"43","author":"Dimitrow","year":"2015","journal-title":"Scand J Public Health"},{"key":"10.1016\/j.jamda.2023.03.003_bib59","first-page":"99","article-title":"Can practical nurses identify older\u00a0home care clients at risk of drug-related problems\u2013geriatricians\u2019 appraisal of their risk screenings: a pilot study","volume":"34","author":"Dimitrow","year":"2018","journal-title":"J\u00a0Pharm Technol"}],"container-title":["Journal of the American Medical Directors Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861023002827?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861023002827?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:31:31Z","timestamp":1761507091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525861023002827"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1525861023002827"],"URL":"https:\/\/doi.org\/10.1016\/j.jamda.2023.03.003","relation":{},"ISSN":["1525-8610"],"issn-type":[{"value":"1525-8610","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review of Psychotropic Adverse Drug Event Monitoring Tools for Use in Long-Term Care Facilities","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Medical Directors Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jamda.2023.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 AMDA - The Society for Post-Acute and Long-Term Care Medicine.","name":"copyright","label":"Copyright"}]}}